|Bid||3.1100 x 1100|
|Ask||3.1200 x 3000|
|Day's Range||3.0499 - 3.4200|
|52 Week Range||2.9100 - 7.5000|
|Beta (5Y Monthly)||-0.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV. INTERACT is the first available FDA interaction and is a key step in the process towards an Investigational New Drug (IND) to study first-in-human products leading to potential marketing approval. LOS ANGELES, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on genetically modified cellular and immune therapy for infectious diseases and cancer, announces that the FDA has scheduled an Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meeting for early June.
Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the acquisition of a novel Hepatitis B Virus (HBV) potential treatment or cure from Seraph Research Institute. At that time, there were no therapies for Hepatitis B. Since that time, I have overseen the development and licensure of several major therapies for the treatment of Hepatitis B and HIV.
At Gilead, Mr. Alton has been Chief Patient Officer and Executive Vice President of International Operations and Corporate Affairs, Executive Vice President of Corporate and Medical Affairs, Secretary and Chief Compliance Officer and General Counsel. Through these and other positions, he was deeply engaged in growing Gilead from a small biotech to one of the largest pharmaceutical companies in the world.
A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells. Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect of the novel therapy. LOS ANGELES, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that important scientific findings reveal an innovative approach to potentially treat and cure Hepatitis B.
Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the expansion of its infectious disease pipeline by entering into an agreement in principle to acquire an exclusive, license for a treatment under development aimed to treat the Hepatitis B Virus (HBV) infections from G-Tech Bio, LLC. An abstract accepted for presentation at the HepDART meeting featuring in vivo and in vitro data from preclinical studies conducted with this novel HBV treatment candidate will be presented by Dr. Serhat Gümrükcü, MD, PhD on December 10, 2019. Approximately 5 percent of the world’s population is infected with HBV, and around 1 million people per year die from the disease.
New York, New York--(Newsfile Corp. - November 21, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Enochain Biosciences, Inc. (NASDAQ: ENOB) ("Enochain" or the "Company").Faruqi & Faruqi logoIf you invested in Enochain stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/ENOB. There is no cost or obligation to you.You can also contact us by calling Richard Gonnello toll free ...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Enochian Biosciences is a pre-clinical stage biotechnology company committed to using its genetically modified cellular and immune-therapy technologies to prevent or potentially cure HIV and to potentially provide life-long cancer remission of some of the deadliest cancers.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! These days it's easy to simply buy an index fund, and your returns should (roughly) match the m...
As with “the Berlin patient,” the first person to be considered “cured” of HIV a decade ago, the intervention utilized in the London patient was performed primarily to treat an HIV-associated cancer. Both patients received transplants with cells from allogeneic donors who have a naturally occurring mutation (CCR5D32) which makes the individuals’ T cells resistant to infection by many types of HIV. These allogeneic bone marrow transplantation procedures require myeloablative chemotherapy, a radical intervention that carries significant medical risks and considerable expense. Given the success of anti-retroviral medicines in managing HIV, this approach is not considered a medically necessary or viable treatment option for HIV-positive persons who do not already require an allogeneic transplant to treat another disease, such as cancer.